Biomet reports Q3 adjusted net income $107.3M vs. $94.9M last year Reports Q4 revenue $822.5M vs. $771.5M last year. The company said knee sales grew 8.4% worldwide, with U.S. growth of 7.7%. Publicly traded peers of Biomet include Zimmer (ZMH) and Stryker (SYK).
News For ZMH;SYK From The Last 14 Days
Check below for free stories on ZMH;SYK the last two weeks.
On The Fly: Analyst Upgrade Summary Today's noteworthy upgrades include: Achillion (ACHN) upgraded to Buy from Hold at Deutsche Bank... CNOOC (CEO) upgraded to Neutral from Underperform at Credit Suisse... Dollar General (DG) upgraded to Buy from Neutral at Sterne Agee... Equity Residential (EQR) upgraded to Hold from Underperform at Jefferies... HMS Holdings (HMSY) upgraded to Overweight from Equal Weight at First Analysis... HP (HPQ) upgraded to Buy from Neutral at Monness Crespi... Halcon Resources (HK) upgraded to Buy from Hold at MLV & Co.... KapStone (KS) upgraded to Buy from Hold at Deutsche Bank... Sportsman's Warehouse (SPWH) upgraded at RW Baird... Westlake Chemical (WLK) upgraded to Neutral from Reduce at SunTrust... WisdomTree (WETF) upgraded to Neutral from Sell at Citigroup... Zimmer (ZMH) upgraded to Outperform from Market Perform at William Blair.
Zimmer upgraded to Outperform from Market Perform at William Blair William Blair upgraded Zimmer Holdings to Outperform citing the recent pullback in shares and its belief the proposed Biomet acquisition will close.
Stryker upcoming analyst day may be catalyst for shares, says Argus Argus believes Stryker is well positioned to post stronger sales and earnings in the second half of the year as new products launch and surgical volume rebounds. The firm thinks the company's analyst day on September 17 could be a catalyst for the shares and it maintains its Buy rating and $102 price target on the stock.